Overview

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

Status:
NOT_YET_RECRUITING
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.
Phase:
PHASE1
Details
Lead Sponsor:
Bostal Drug Delivery Co., Ltd